Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05918640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Lurbinectedin in FET-Fused Tumors

Study acronym: LiFFT
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 30, 2027 → Jul 30, 2028
See other at-risk trials from Children's Hospital of Philadelphia

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Jul 30, 2027 to Jul 30, 2028
    • Study completion pushed from Jul 30, 2028 to Jul 30, 2029
    v20
  2. Eligibility criteria revisedv19
  3. Primary completion date: Jul 30, 2026 to Jul 30, 2027
    • Eligibility criteria expanded, about 33 words
    v18
  4. Site contacts updated at 1 of 6 sitesv17
  5. Re-verified, no change to tracked fieldsv16
Show 14 earlier versionsHide 14 earlier versions
  1. Study sites: 7 to 6v15
  2. Enrollment target: 56 to 63
    • Eligibility criteria shortened, about 6 words
    v14
  3. Site details revised at 1 of 7 sitesv13
  4. Site details revised at 1 of 7 sitesv12
  5. Eligibility criteria expanded, about 20 wordsv11
  6. Study sites: 6 to 7v10
  7. Site details revised at 1 of 6 sitesv9
  8. Site details revised at 3 of 6 sitesv8
  9. Study sites: 5 to 6v7
  10. Study sites: 4 to 5v6
  11. Eligibility criteria expanded, about 15 wordsv5
  12. Study sites: 1 to 4v4
  13. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 2023 to Jul 27, 2023
    • Site details revised
    v3
  14. Primary completion date: Jun 30, 2026 to Jul 30, 2026
    • Study completion date: Jun 30, 2028 to Jul 30, 2028
    • Start date: Jun 2023 to Jul 2023
    • Site contact updated
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.
Trial Details
NCT Number NCT05918640
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Jazz Pharmaceuticals, Stand Up To Cancer
Conditions
(from sponsor)		 Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
Related terms Desmoplastic Small Round Cell Tumor, Neoplasms, Sarcoma, Ewing
Enrollment 63 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov